Diabetes drug found to improve cardiovascular outcomes across a range of heart and kidney conditions

[Health - Medical Xpress - latest medical and]

A new meta-analysis shows sodium glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of major adverse cardiovascular events in patients with either diabetes at high risk of atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease (CKD). Findings were presented at the American College of Cardiology Annual Scientific Session & Expo and simultaneously published in Circulation.

Continue reading...